earnings
confidence high
sentiment neutral
materiality 0.60
Gain Therapeutics Reports Q3 2025 Results and Phase 1b Data for GT-02287 in Parkinson's Disease
Gain Therapeutics, Inc.
2025-Q3 EPS
reported -$0.50
vs consensus -$0.15
▼ miss
(-226.8%)
- Completed enrollment of 21 participants in Phase 1b study of GT-02287, surpassing original target of 15.
- Initial data from first nine participants showed improvement in MDS-UPDRS scores, suggesting disease-slowing effect.
- Received Australian approval to extend Phase 1b dosing to 12 months; ~80% of participants joined extension.
- Net loss for Q3 2025 was $0.15 per share; cash and cash equivalents $8.8 million as of September 30, 2025.
- R&D expenses increased to $2.8 million from $2.6 million year-over-year, driven by Phase 1b trial costs.